Retatrutide vs Tirzepatide vs Semaglutide: What the Human Trials Actually Show in 2026
A pseudonymous reader walks through every Phase 3 (and one Phase 2) trial behind the three most-searched GLP-1 molecules of the year, side by side, with the effect sizes, the funding, and the gaps.
by JoyBoy
14 min read
Last reviewed May 2026
🟢 Human RCT (all three)
Two FDA-approved, one not yet
Why I looked into this
If you searched for any of these three molecules in 2026, you ran into the same problem I did. Half the results are vendor blogs trying to sell you something. The other half are clinical trial PDFs that nobody links together in plain language. The middle is missing.
This piece is the middle. I read every Phase 3 publication for Semaglutide and Tirzepatide, the single Phase 2 publication for Retatrutide, and the relevant labels and FDA briefing documents. I am writing the comparison I wish someone had written for me before I started reading the literature myself.
One thing up front: I have used Retatrutide personally for about a month. That experience belongs in the opinion section at the bottom, not the evidence section. The data and the diary live in separate rooms on this site.
The three molecules at a glance
The simplest honest framing is by receptor count.
Semaglutide is a single-receptor agonist. It binds the GLP-1 receptor. Natural GLP-1 is a gut hormone released after eating. Semaglutide is the engineered long-acting version that survives in the bloodstream for days instead of minutes. The downstream effects are slowed gastric emptying, glucose-dependent insulin secretion, and reduced appetite signaling in the brain. Approved as Ozempic for type 2 diabetes in 2017, Wegovy for chronic weight management in 2021, and Rybelsus (oral) in 2019. Maker: Novo Nordisk.
Tirzepatide is a dual-receptor agonist. It binds GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is a second incretin hormone with its own metabolic effects, including on adipose tissue handling. Adding GIP activity to GLP-1 activity, in theory, gets you a different metabolic phenotype than GLP-1 alone. The Phase 3 data confirms it gets you more weight loss. Approved as Mounjaro for type 2 diabetes in 2022, Zepbound for chronic weight management in 2023. Maker: Eli Lilly.
Retatrutide is a triple-receptor agonist. It binds GLP-1, GIP, and the glucagon receptor. The glucagon piece is the interesting one. Glucagon raises blood sugar (the opposite of insulin), but it also increases energy expenditure. The bet behind a triple agonist is that you get the appetite suppression of GLP-1, the metabolic effects of GIP, and the energy-burn nudge of glucagon, all in one molecule, with the dose-limiting nausea of any single one of them held in check by the cross-talk. The Phase 2 data suggests the bet is paying off. Phase 3 trials are ongoing. Maker: Eli Lilly.
What the human research shows on weight loss
How much weight loss did each drug produce in its biggest published trial?
Head-to-head against placebo, in roughly comparable adult populations, the published numbers are:
- Semaglutide, STEP 1 (Wilding et al, NEJM 2021): ~14.9% mean weight loss at 68 weeks at 2.4 mg weekly, n=1,961, placebo ~2.4%. Industry funded (Novo Nordisk).
- Tirzepatide, SURMOUNT-1 (Jastreboff et al, NEJM 2022): ~22.5% mean weight loss at 72 weeks at the highest evaluated weekly amount, n=2,539, placebo ~2.4%. Industry funded (Eli Lilly).
- Retatrutide, Phase 2 (Jastreboff et al, NEJM 2023): ~24.2% mean weight loss at 48 weeks at the highest evaluated weekly amount, n=338, placebo ~2.1%. Industry funded (Eli Lilly).
Are these comparable trials?
Roughly, yes. All three were placebo-controlled, all enrolled adults with obesity (or overweight plus a comorbidity), all measured weight at predefined endpoints. The Retatrutide trial was 48 weeks rather than 68 or 72, which makes the magnitude even more striking, with the caveat that Phase 2 trials are smaller, shorter, and less robust than Phase 3.
None of these were head-to-head trials. Semaglutide vs Tirzepatide head-to-head data does exist in type 2 diabetes (the SURPASS-2 trial showed Tirzepatide more effective on A1c at all evaluated levels), but the cleanest weight-loss numbers come from each drug’s own pivotal obesity trial. Comparing across trials is imperfect. The trend is clear anyway.
What does the research NOT show?
It is worth saying plainly what the trials did not establish:
- That weight loss is permanent after stopping. The STEP 4 extension data shows substantial weight regain after discontinuation.
- That a triple agonist is necessarily safer than a dual or single. Phase 2 cannot answer that. Phase 3 might.
- That any of these is a substitute for the parts of metabolic health that diet, training, sleep, and labs actually measure.
- That research-chemical-grade copies of these molecules behave the same way as the FDA-approved versions. They have not been tested.
Cardiovascular and metabolic outcomes
Weight loss is the headline. Cardiovascular outcomes are the underrated story.
Semaglutide has the most cardiovascular outcomes data. The SELECT trial (Lincoff et al, NEJM 2023) randomized 17,604 patients with overweight or obesity and established cardiovascular disease to Semaglutide 2.4 mg weekly versus placebo, with a mean follow-up of ~3.3 years. The composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was reduced by ~20%. That is the kind of result that changes the regulatory conversation, and it did: the FDA added a cardiovascular indication to the Wegovy label in 2024.
Tirzepatide has the SURPASS-CVOT trial ongoing, with topline results expected in the 2026 to 2027 window. As of writing, the cardiovascular outcomes evidence for Tirzepatide is implied from biomarker improvements in the SURPASS and SURMOUNT programs but not yet established by a dedicated outcomes trial.
Retatrutide has no cardiovascular outcomes trial yet. Phase 3 trials including a cardiovascular outcomes program are in flight. We do not have the answer.
Side effect comparison (what the trials actually reported)
All three molecules produce gastrointestinal side effects. Nausea, vomiting, diarrhea, constipation, and reflux are the most common across the trials. Most are mild to moderate. Most attenuate over weeks. Most resolve at the lowest evaluated weekly amount.
Across the pivotal trials:
- Semaglutide STEP 1: ~74% of the active arm had any GI adverse event vs ~48% on placebo. Discontinuation for adverse events ~7%.
- Tirzepatide SURMOUNT-1: GI events similar in pattern, with intensity skewed toward the higher amounts. Discontinuation for adverse events ~6.6% at the highest evaluated weekly amount.
- Retatrutide Phase 2: GI events more pronounced at the highest evaluated weekly amount, including a higher rate of vomiting compared to Tirzepatide-class trials. Discontinuation for adverse events ~16% at the highest evaluated amount.
The Retatrutide GI tolerability number is the part nobody on the biohacker side of the internet seems to want to talk about. Triple agonism is biologically interesting and produces more side effects, especially at the high end. Phase 3 will show whether titration patterns can manage that.
All three carry warnings about pancreatitis, gallbladder disease, and (in animal studies) thyroid C-cell tumors. These are class-level concerns, not trivia, and the labels reflect them.
FDA and legal status
FDA approved. Ozempic (2017), Wegovy (2021), Rybelsus (2019). Cardiovascular indication added 2024. Schedule: not controlled. Prescription only.
FDA approved. Mounjaro (2022), Zepbound (2023). Schedule: not controlled. Prescription only. Cardiovascular outcomes trial pending.
Not approved. Phase 3 trials ongoing. Available in trials and a small number of expanded-access pathways. Not 503A-eligible at the FDA-approved drug shortage level (because it is not yet an approved drug).
Compounding rules around Semaglutide and Tirzepatide tightened sharply in late 2024 and 2025 as the FDA moved both off the shortage list. The legitimate compounding pathway for these two is narrower than it was. Retatrutide is not a compounded drug at all in the consumer sense.
The legal landscape for all three changed materially between 2023 and 2026. Semaglutide and Tirzepatide compounding pathways narrowed. Retatrutide remains a research-stage molecule, with the gray-market suppliers (whom I do not name) selling research-use-only material that is not the same product as the trial drug.
I built a doctor visit-prep one-pager specifically for the GLP-1 conversation. Evidence summary, side effect questions, and what to ask before starting. Free PDF. No upsell.
Get the GLP-1 visit-prep one-pagerHow to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name sellers. I do not link to anyone. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
Green flags
- For Semaglutide and Tirzepatide: a real prescription from a clinician you can talk to, filled at a licensed pharmacy
- For Retatrutide: enrollment in a clinical trial or a clinically supervised expanded-access program
- Independent third-party testing of any compounded product (now narrower than it used to be)
- A clinician who is willing to say “this is not a good fit for you” and walk away
- Disclosure of where the compound is synthesized and tested
Red flags
- “Research use only” labeling on a vial that is being marketed for human use
- Anyone offering “Retatrutide” as a finished injectable product outside a clinical trial
- Compounded GLP-1 products being marketed as if the 2023 era still applied
- Urgency or scarcity language (“last batch”, “before the FDA shuts it down”)
- Refusal to provide independent third-party lab testing
The wrinkle for this comparison specifically
The legitimate version of two of these three is a prescription drug at a licensed pharmacy. The legitimate version of the third is a clinical trial. Anyone selling you “the same molecule” outside those two channels is asking you to trust their lab work over the FDA’s. That trust may or may not be warranted. Independent third-party testing is the only way to find out, and most of the gray-market product on offer in 2026 cannot or will not show it.
Cost reality
The list price of Wegovy and Zepbound is high, and insurance coverage is uneven. The compounded versions that flooded the market during the 2022 to 2024 shortage window have largely lost their legal pathway. The price gap that drove people toward research chemicals in the first place is real. The sterility-and-purity gap that comes with it is also real. There is no free lunch in this transaction.
Questions worth asking any source
Where is this synthesized? Where is it independently tested? Who is the prescribing clinician of record? What happens if I have a reaction? A real source has answers. A bad one has marketing copy.
My 503A Source-Safety Checklist is the single most useful tool on this site. Free PDF. No upsell. It is what I use myself.
Download the source-safety checklistMy honest take
This section is opinion, not evidence. I am not endorsing use of any of these molecules. Everything above this line is sourced from published human research and regulatory documents. Everything below is my personal perspective as one pseudonymous reader and user. It is not medical advice. Your situation is not my situation. Do not treat this as a recommendation to try anything.
I have used Retatrutide personally for about a month, while it was available to me through a legitimate channel. The experience was positive for me. Appetite signaling changed in a way that felt different from what I had read about Semaglutide. I cannot tell you what your experience would be, because we are different people, in different situations, with different baseline biology.
“A triple agonist is not ‘three times the GLP-1.’ It is a different molecule with a different metabolic footprint, and the way it feels reflects that.”
Two things I would push back on if I heard them at a cocktail party. First, “Retatrutide is just a better Tirzepatide” is wrong. The receptor profiles are different. The Phase 2 numbers are higher and the side effect profile is different too. The Phase 3 trials are the ones that will tell us whether the math works at the population level. Second, “Semaglutide is yesterday’s news” is also wrong. Semaglutide has the cardiovascular outcomes data. That is not a small thing.
“Of the three, Semaglutide has the strongest evidence base, Tirzepatide has the highest weight loss with cardiovascular data on the way, and Retatrutide is the most exciting Phase 2 result of the decade. They are not interchangeable.”
If I had to summarize the three for a friend asking “which should I be thinking about,” I would say: Semaglutide is the settled drug, Tirzepatide is the upgrade with stronger near-term effect, Retatrutide is the bet on the next generation. Which one fits depends on goals, situation, and a clinician who actually knows you. None of that is in this article. That is the part you bring to the appointment.
Questions to ask your doctor
If you are considering any of the three, here are the questions I would want answered before walking out of the appointment, in order.
- Given my situation, which of the three (if any) is the right conversation? Type 2 diabetes, cardiovascular history, weight management, and other goals push the answer in different directions. The answer should be specific to you, not to “GLP-1 in general.”
- What is your stop condition? Under what circumstance would you discontinue, and what is the expected weight regain trajectory? STEP 4 data exists. Most clinicians do not bring it up unprompted.
- How will we monitor side effects, and at what threshold do we change course? Pancreatitis, gallbladder, severe nausea, and the more rare events deserve a written plan, not a vague “let me know if anything happens.”
- What about pregnancy and contraception? All three carry meaningful pregnancy considerations. If this is relevant for you, it should be addressed before the first dose, not after.
- Are we using the FDA-approved product or a compounded version? If compounded, why, and what is the chain of custody? In 2026, the compounding answer is materially different than it was in 2023.
- What is the realistic timeline for the cardiovascular outcomes data on Tirzepatide and Retatrutide, and does that change your recommendation today? A clinician who has read the labels can answer this in one sentence.
I built a peptide-specific visit-prep packet to take into your appointment. Evidence summary, doctor questions, space for notes. Free PDF.
Get the visit-prep packetWhat to do next
If you are curious
Read the individual monographs. Each one walks the trial data in detail. Pick the molecule that matches your actual situation rather than the one with the loudest YouTube thumbnail.
Read the Semaglutide monograph →If you are considering
Have the conversation with a clinician you can actually reach. Bring the visit-prep packet. Bring your goals. Bring your stop condition before you start.
Get the visit-prep packet →If you have decided
Use the source-safety checklist before committing to any provider or pharmacy, especially given how the compounding rules changed in 2024 and 2025.
Download the source-safety checklist →Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. Industry funded (Novo Nordisk).
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. Industry funded (Eli Lilly).
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389:514-526. Industry funded (Eli Lilly).
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232. Industry funded (Novo Nordisk).
- US FDA. Wegovy prescribing information, updated cardiovascular indication 2024.
- US FDA. Zepbound prescribing information.
- US FDA. Notices regarding the resolution of Semaglutide and Tirzepatide drug shortage status, 2024 to 2025.
Funding for the pivotal trials is largely industry. That is worth saying plainly. Industry funding does not invalidate the data, but it is part of how the data should be read.
Related monographs
Semaglutide
The settled drug. Multiple Phase 3 programs, cardiovascular outcomes data.
Tirzepatide
The dual-receptor upgrade. Higher weight loss, cardiovascular trial pending.
Retatrutide
The triple-agonist Phase 2 result that changed the conversation.
The Peptide File provides educational content based on published research. This article is not medical advice. The Peptide File does not sell, distribute, or facilitate the purchase of any peptide compound. Always work with a qualified healthcare provider.